IONIS PHARMACEUTICALS, INC.

IONIS PHARMACEUTICALS, INC. logo
🇺🇸United States
Ownership
Public, Private, Subsidiary
Established
1989-01-01
Employees
927
Market Cap
-
Website
http://www.ionis.fr

Safety, Tolerability and Activity Study of Multiple Doses of ISIS-SGLT2Rx in Healthy Volunteers

Phase 1
Completed
Conditions
Interventions
First Posted Date
2009-02-04
Last Posted Date
2012-02-03
Lead Sponsor
Ionis Pharmaceuticals, Inc.
Target Recruit Count
103
Registration Number
NCT00836225
Locations
🇳🇱

Center for Human Drug Research, Leiden, Netherlands

Safety and Tolerability of Single and Multiple Doses of ISIS 353512 in Healthy Volunteers

Phase 1
Completed
Conditions
Interventions
First Posted Date
2008-08-14
Last Posted Date
2010-07-29
Lead Sponsor
Ionis Pharmaceuticals, Inc.
Target Recruit Count
103
Registration Number
NCT00734240
Locations
🇨🇦

Anapharm, Montreal, Quebec, Canada

Safety Study of ISIS 325568 in Healthy Volunteers

Phase 1
Completed
Conditions
Interventions
First Posted Date
2007-08-23
Last Posted Date
2008-08-19
Lead Sponsor
Ionis Pharmaceuticals, Inc.
Target Recruit Count
60
Registration Number
NCT00519727
Locations
🇳🇱

Centre for Human Drug Research, Leiden, Netherlands

Placebo Controlled, Dose Escalation Study in Subjects With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea

Phase 2
Completed
Conditions
Interventions
First Posted Date
2007-04-03
Last Posted Date
2009-08-28
Lead Sponsor
Ionis Pharmaceuticals, Inc.
Target Recruit Count
88
Registration Number
NCT00455598
Locations
🇷🇴

Oradea Clinical County Hospital, Department of Diabetes, Nutrition and Metabolic Diseases, Oradea, Romania

🇷🇺

Limited Liability Company "Clinic of New Medical Technologies", Moscow, Russian Federation

🇷🇴

Private Practice "Morosanu V. Magdalena", Galati, Romania

and more 36 locations

Examination of Dermatologic Effects From Subcutaneous Injections of ISIS 113715

Phase 1
Completed
Conditions
First Posted Date
2006-08-17
Last Posted Date
2007-10-17
Lead Sponsor
Ionis Pharmaceuticals, Inc.
Target Recruit Count
10
Registration Number
NCT00365781
Locations
🇺🇸

Therapeutics Clinical Research, San Diego, California, United States

Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Who Have Not Received Prior Treatment

Phase 2
Completed
Conditions
First Posted Date
2006-05-26
Last Posted Date
2008-02-06
Lead Sponsor
Ionis Pharmaceuticals, Inc.
Target Recruit Count
96
Registration Number
NCT00330330
Locations
🇷🇺

Close Corporation "MEDSI", Moscow, Russian Federation

🇵🇱

NZOZ Specjalistyczny Osrodek Internistyczno Diabetologiczny, Bialystok, Poland

🇵🇱

Prywatna Praktyka Lekarska, Radom, Poland

and more 7 locations

Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and Energy Expenditure in Type 2 Diabetics

Phase 2
Terminated
Conditions
First Posted Date
2006-05-26
Last Posted Date
2022-12-05
Lead Sponsor
Ionis Pharmaceuticals, Inc.
Target Recruit Count
2
Registration Number
NCT00330200
Locations
🇺🇸

Yale - New Haven Hospital, New Haven, Connecticut, United States

Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea

Phase 2
Withdrawn
Conditions
First Posted Date
2006-05-18
Last Posted Date
2022-12-05
Lead Sponsor
Ionis Pharmaceuticals, Inc.
Registration Number
NCT00327626
Locations
🇮🇱

Rambam Medical Center, Haifa, Israel

🇮🇱

Western Galilee Medical Center - Nahariya, Nahariya, Israel

🇮🇱

Soroka Medical Center, BeEr-Sheva, Israel

and more 2 locations

Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer

Phase 3
Completed
Conditions
First Posted Date
2004-02-04
Last Posted Date
2022-12-05
Lead Sponsor
Ionis Pharmaceuticals, Inc.
Registration Number
NCT00017407
Locations
🇺🇸

Ireland Cancer Center, Cleveland, Ohio, United States

🇺🇸

ISIS Pharmaceuticals, Inc., Carlsbad, California, United States

© Copyright 2024. All Rights Reserved by MedPath